Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity

In the last years, Stereotactic body radiotherapy (SBRT) has demonstrated to be an effective and safe treatment option for localized prostate cancer (PCa) in low and intermediate-risk patients, by producing comparable results to conventional and softly-hypofractionated schedules [1 –3]. Prostate SBRT requires high precision in patients' positioning to ensure an accurate dose delivery. Prostate SBRT is generally characterized by a low rate of side effects, and few predictive factors are available to identify the early onset of symptoms [4].

https://www.thegreenjournal.com/article/S0167-8140(23)09350-7/fulltext?rss=yes

Source: Radiotherapy and Oncology - December 4, 2023 Category: Radiology Authors: Luca Nicosia, Paolo Ravelli, Michele Rigo, Niccol ò Giaj-Levra, Rosario Mazzola, Edoardo Pastorello, Francesco Ricchetti, Andrea Gaetano Allegra, Ruggero Ruggieri, Filippo Alongi Tags: Original Article Source Type: research